| Literature DB >> 31709528 |
Huijuan Yang1,2, Shuang Ye1,2, Shyamal Goswami3, Teng Li3, Jingwen Wu1,2, Chunmei Cao4, Jiaqiang Ma3, Bin Lu5, Xuan Pei1,2, Yanan Chen3, Jing Yu3, Huihui Xu3, Liwei Qiu3, Saifullah Afridi3,6, Libing Xiang1,2, Xiaoming Zhang3.
Abstract
Regulatory T cells (Tregs) are crucial for the maintenance of peripheral tolerance, but they also limit beneficial responses through cancer-induced immunoediting. The roles of Treg subsets in cervical squamous cell carcinoma (CSCC) are currently unknown. Here, we aimed to perform an extensive study with an increased resolution of the Treg compartment in the peripheral blood and tumor tissues of CSCC patients. We first identified that an HLADRhi Treg population in the peripheral blood was significantly increased in CSCC patients compared to precancer patients and healthy donors. We found that HLADRhi Tregs express high levels of a panel of inhibition and activation markers and the TCR-responsive transcription factors BATF and IRF4. However, this Treg subset showed reduced calcium influx after TCR crosslinking. In addition, HLADRhi Tregs are highly proliferative and vulnerable to apoptosis. Further studies demonstrated that the HLADRhi Tregs display high levels of suppressive activity. Quantitative multiplexed immunohistochemistry revealed that an increase in the number of tumor-infiltrating HLADRhi Tregs is associated with unfavorable classical risk parameters of advanced disease stage and stromal invasion. Context-based quantification revealed that a high frequency of stromal HLADRhi Tregs in patients is significantly associated with worse progression-free survival. In the current study, we characterized a population of highly activated and immunosuppressive HLADRhi Tregs in CSCC patients. An increased HLADRhi Treg frequency may be a potential biomarker to stratify CSCC patients and evaluate therapeutic efficacies in personalized immuno-oncology studies.Entities:
Keywords: cervical squamous cell carcinoma; immune suppression; multiplexed immunohistochemistry; progression-free survival; regulatory T cells
Mesh:
Substances:
Year: 2019 PMID: 31709528 DOI: 10.1002/ijc.32782
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396